Back to Dashboard

C1071005

MM•NCT05020236•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

1. Elranatamab 2. Elranatamab+Dara

Mechanism of Action

BCMA-Bite

Sponsor

Unknown

Design

III

Control Arm

-

Criteria

Inclusion Criteria

≥2 prior Tx (Including Lenalidomide and Proteasome Inhibitor )

Age: Phase: III

Exclusion Criteria

Enrollment

Progress3 / 10

Contact Information

Principal Investigator

Unknown

Study Nurse

曾睦捷

Contact Tel

4620